Type and timing of antiretroviral therapy during pregnancy: Impact on risk of preterm delivery and small-for-gestational age births in Canada, a retrospective cohort study.
Canada
HIV
antiretroviral therapy
pregnancy
preterm delivery
small for gestational age birth
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
03
01
2023
received:
25
05
2022
accepted:
27
01
2023
medline:
21
7
2023
pubmed:
28
1
2023
entrez:
27
1
2023
Statut:
ppublish
Résumé
To evaluate the impact of type and timing of antiretroviral therapy (ART) on the risk of preterm delivery (PTD) and small-for-gestational age (SGA) birth among pregnant women and people living with HIV in Canada. Data for this retrospective cohort study were analyzed from the Canadian Perinatal HIV Surveillance Program from 1990 to 2020. The association between ART and risk of PTD (<37 weeks) and SGA birth (<10th percentile) was explored using mixed effects logistic regression and time-dependent Cox proportional hazards models. Overall, there were 14.9% (654 of 4379) PTD and 18.5% (732 of 3947) SGA cases. A higher risk of PTD was observed with nonnucleoside reverse transcriptase inhibitor-(adjusted hazard ratio [aHR], 1.73; P = 0.019) and boosted protease inhibitor- (aHR, 186; P = 0.007) based regimens compared with integrase strand transfer inhibitor (INSTI)-based regimens. ART initiation prior to conception was associated with a lower risk of SGA birth compared with ART initiation after conception at 1 to 14 weeks (adjusted odds ratio [aOR], 0.69; P = 0.024) and > 14 weeks (aOR, 0.70; P = 0.005). INSTI-based ART regimens were associated with lower risk of PTD compared with other regimens, and ART initiation before conception was associated with a lower risk of SGA birth. These findings, with overall safety data, should be considered when providing pregnancy counseling to people living with HIV.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
614-622Subventions
Organisme : Fonds de Recherche du Québec - Santé
Organisme : Public Health Agency of Canada
Informations de copyright
© 2023 The Authors. International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.
Références
Lopez M, Figueras F, Hernandez S, et al. Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART. Aids. 2012;26(1):37-43.
Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206(11):1695-1705.
Arab K, Spence AR, Czuzoj-Shulman N, Abenhaim HA. Pregnancy outcomes in HIV-positive women: a retrospective cohort study. Arch Gynecol Obstet. 2017;295(3):599-606.
Forbes JC, Alimenti AM, Singer J, et al. A national review of vertical HIV transmission. Aids. 2012;26(6):757-763.
Carvalho S, Lee T, Tulloch K, et al. Prescribing patterns of antiretroviral treatments during pregnancy for women living with HIV in Canada 2004-2020: a surveillance study. HIV Med. 2022. https://doi.org/10.1111/hiv.13346
Albert AY, Elwood C, Wagner EC, et al. Investigation of factors associated with spontaneous preterm birth in pregnant women living with HIV. Aids. 2020;34(5):719-727.
Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric Spectrum of HIV disease, 1989-2004. Pediatrics. 2007;119(4):e900-e906.
Kakkar F, Boucoiran I, Lamarre V, et al. Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting? J Int AIDS Soc. 2015;18(1):19933.
Ravizza M, Martinelli P, Bucceri A, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis. 2007;195(6):913-914.
Short CE, Douglas M, Smith JH, Taylor GP. Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission. HIV Med. 2014;15(4):233-238.
Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381(9):827-840.
Favarato G, Townsend CL, Bailey H, et al. Protease inhibitors and preterm delivery: another piece in the puzzle. Aids. 2018;32(2):243-252.
Snijdewind IJ, Smit C, Godfried MH, et al. Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age. PloS One. 2018;13(1):e0191389.
Kramer MS, Platt RW, Wen SW, et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001;108(2):e35.
Papp E, Mohammadi H, Loutfy MR, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis. 2015;211(1):10-18.
van der Merwe K, Hoffman R, Black V, Chersich M, Coovadia A, Rees H. Birth outcomes in south African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc. 2011;14(1):1-11.
Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Transmission in the United States. (2020). https://clinicalinfo.hiv.gov/en/guidelines/perinatal/overview
European Aids Clinical Society. (2020). EACS Guidelines [version 10.1]. https://www.eacsociety.org/media/guidelines-10.1_finaljan2021_1.pdf
Venter WD, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803-815.
Lake JE, Trevillyan J. Impact of integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV. Curr Opin HIV AIDS. 2021;16(3):148-151.
Joseph NT, Satten GA, Williams RE, et al. The effect of antiretroviral therapy for the treatment of human immunodeficiency virus (HIV)-1 in pregnancy on gestational weight gain. Clin Infect Dis. 2021;75(4):665-672.
Nadeau-Vallée M, Obari D, Palacios J, et al. Sterile inflammation and pregnancy complications: a review. Reproduction. 2016;152(6):R277-R292.
Richter LL, Ting J, Muraca GM, et al. Temporal trends in preterm birth, neonatal mortality, and neonatal morbidity following spontaneous and clinician-initiated delivery in Canada, 2009-2016. J Obstet Gynaecol Can. 2019;41(12):1742-1751.
El Adam S, Hutcheon JA, McLeod C, McGrail K. Why are babies in Canada getting smaller? Health Rep. 2022;33(1):3-16.
Shah PS, Zao J, Al-Wassia H, Shah V, Knowledge Synthesis Group on Determinants of Preterm/LBW Births. Pregnancy and neonatal outcomes of aboriginal women: a systematic review and meta-analysis. Womens Health Issues. 2011;21(1):28-39.